The chances of “small triple yang” turning negative on its own are low, with an annual incidence of only 0.5%-1%, and the time required for the whole process of turning negative varies from individual to individual, so no definite time can be generalized. Most of the patients with “small triplet” can be converted after treatment. The rate of reversion varies with different antiviral regimens: with pegylated interferon antiviral therapy, the rate of reversion is about 3% after 48 weeks of treatment; with pegylated interferon, the rate of reversion can reach 8% after three years of discontinuation; with oral nucleoside (acid) analogs (entecavir, tenofovir, propofol tenofovir) alone, the rate of reversion to surface antigen is less than 3%. Currently, oral nucleoside analogs combined with long-acting interferons have led to a significant increase in surface antigen regression rates, but still account for less than 20% of the overall hepatitis B population. In addition, small triple-positive virus carriers with no conscious symptoms and normal liver function and no fibrosis of the liver do not need treatment and are clinically in the immune tolerance period, which generally does not affect normal life.
Support Us
Discussion
Share your experience, or seek help from fellow patients.
